antiviral and associated therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.00 [0.92, 1.08]< 15%16 studies (16/-)51.6 %some concernlow moderatecrucial-
death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %NAnot evaluable crucial-
deaths 0.98 [0.93, 1.03]< 10%46 studies (46/-)82.5 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.93 [0.83, 1.04]< 148%12 studies (12/-)89.9 %some concerncritical moderatecrucial-
clinical deterioration 0.98 [0.74, 1.31]< 127%10 studies (10/-)54.9 %some concernlow moderateimportant-
clinical improvement 1.18 [1.01, 1.38]> 155%16 studies (16/-)98.2 %some concernlow moderateimportant-
clinical improvement (14-day) 1.07 [0.89, 1.27]> 148%17 studies (17/-)76.1 %some concernlow moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %NAnot evaluable important-
clinical improvement (28-day) 1.24 [1.03, 1.50]> 154%9 studies (9/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.20 [0.99, 1.45]> 153%12 studies (12/-)97.1 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.22 [1.10, 1.36]> 133%12 studies (12/-)100.0 %some concernlow moderateimportant-
death or ventilation 1.02 [0.95, 1.10]< 120%8 studies (8/-)28.5 %some concernnot evaluable moderateimportant-
hospital discharge 0.98 [0.88, 1.08]> 151%11 studies (11/-)31.0 %some concernlow moderateimportant-
mechanical ventilation 0.91 [0.73, 1.12]< 137%18 studies (18/-)81.4 %some concernlow moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %NAnot evaluable important-
radiologic improvement (14-day) 1.17 [0.42, 3.26]> 116%3 studies (3/-)62.1 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.09 [0.01, 0.78]> 10%2 studies (2/-)1.5 %some concernnot evaluable moderateimportant-
viral clearance 1.47 [1.01, 2.13]> 166%9 studies (9/-)97.7 %some concernserious moderateimportant-
viral clearance (time to event analysis only) 1.32 [1.03, 1.69]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.99 [0.93, 1.06]> 10%8 studies (8/-)40.5 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.01 [0.84, 1.21]> 128%8 studies (8/-)53.7 %some concernnot evaluable moderateimportant-
ICU admission 0.91 [0.75, 1.10]< 10%11 studies (11/-)84.2 %some concernlow moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.09 [0.95, 1.26]> 147%5 studies (5/-)89.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %NAnot evaluable important-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 0.85 [0.71, 1.01]< 10%20 studies (20/-)96.5 %